Search

Displaying results 3721 - 3730 of 7063 in total
  1. Drug

    Perphenazine

    go.drugbank.com/drugs/DB00850
    ApprovedInvestigational

    An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

    Mixtures: Etrafon D Tab, Etrafon A TabCategories: Dopamine D2 Receptor Antagonists
  2. Drug

    Piflufolastat F 18

    go.drugbank.com/drugs/DB14805
    ApprovedInvestigational

    Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in many tissues that plays a role in folate uptake and neurotransmitter release - it is expressed in the prostate at … [A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues.

  3. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a

  4. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]

  5. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases. … [L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.

  6. Drug

    Thyroid, porcine

    go.drugbank.com/drugs/DB09100
    ApprovedInvestigational

    [A190813] Thyroid extracts were never FDA approved as their use in the United States predates the FDA.[A190831] … [A190831] Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet.

  7. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    Eszopiclone was initially approved by the FDA in 2004.[L6769] … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.

  8. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. … It is the active descarboethoxy metabolite of loratidine (a second generation histamine).

    Mixtures: Clarinex-D 12 Hour, Clarinex-D 24 HourProducts: GLOBISTAMIN D, GLOBISTAMIN D JARABE
  9. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. … Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.

  10. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test. … Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon.